KIMMTRAK 100 micrograms/0.5 mL concentrate for solution for infusion

DRUG4 trials

Sponsors

Immunocore Limited, Grupo Espanol Multidisciplinar De Melanoma, European Organisation For Research And Treatment Of Cancer

Conditions

Metastatic uveal melanoma with resectable liver metastasis and absence of extra-liver diseasePreviously treated non-ocular advanced melanomaPreviously untreated advanced uveal melanoma (UM)Uveal Melanoma

Phase 2

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

RecruitingCTIS2022-502732-39-00

Immunocore LimitedPreviously treated non-ocular advanced melanoma

Start: 2023-09-01Target: 363Updated: 2025-10-14

A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator’s Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma

CompletedCTIS2024-517290-24-00

Immunocore LimitedPreviously untreated advanced uveal melanoma (UM)

Start: 2017-12-19End: 2025-09-17Target: 96Updated: 2025-06-25

Neoadjuvant Tebentafusp in Patients with Metastatic Uveal Melanoma

RecruitingCTIS2023-509076-42-00

Grupo Espanol Multidisciplinar De MelanomaMetastatic uveal melanoma with resectable liver metastasis and absence of extra-liver disease

Start: 2025-07-18Target: 19Updated: 2025-10-21

Phase 3

EORTC 2022-MG: Adjuvant tebentafusp (IMCgp100) versus observation in HLA-A*02:01 positive patients following definitive treatment of high-risk uveal melanoma: an EORTC randomized phase III study (ATOM Trial)

RecruitingCTIS2023-510333-28-00

European Organisation For Research And Treatment Of CancerUveal Melanoma

Start: 2025-08-20Target: 200Updated: 2025-12-15